Abzena and UGA Biopharma Announce a Cell Line Expressing a Biosimilar to an Antibody Therapeutic for MS

Biosimilar News  •  Deal Watch

On October 19, 2017, Abzena plc and UGA Biopharma Gmbh announced that their partnership completed development of an NS0 (murine myeloma) manufacturing cell line.  This cell line expresses a biosimilar of a therapeutic antibody for multiple sclerosis. While the press release does not disclose the originator therapeutic, it notes the originator therapeutic had worldwide sales of approximately $1.9 billion in 2016.

Download PDF

Comments are closed.